The sequential deterioration in gross margin, from 36.1% in 2025Q3 to 30.7% in 2026Q2, suggests that the company is facing persistent input cost pressures or unfavorable product mix shifts, not just one-off charges. Operating margin at 2.3% in 2026Q2, down from 10.0% in 2024Q4, implies that fixed costs are not being adequately covered by the shrinking revenue base, which may indicate a structural profitability problem rather than a temporary cyclical dip. Investors should monitor whether management can stabilize gross margin above 33% in coming quarters, as the current trajectory suggests further downside risk.

The near-zero ROIC across the last ten quarters, with a peak of only 1.1% in 2024Q4, suggests that Perrigo's asset base is not being deployed efficiently to generate profits. The sharp decline in equity, from $4.4B in 2025Q3 to $2.5B in 2026Q2, due to cumulative losses and goodwill impairments, has artificially inflated ROE in 2026Q2, but this is not a sign of operational improvement. The company's return on capital appears to be decaying, as margins remain weak and asset turnover is stagnant at 0.13, implying that the business is not compounding value for shareholders.

The increase in days inventory outstanding from 138 days in 2024Q4 to 140 days in 2026Q2, coupled with a stable DSO around 60-66 days, suggests that Perrigo is holding more inventory relative to sales, which may tie up cash and increase the risk of write-downs. The cash conversion cycle of 153 days is notably high, indicating that the company takes over five months to convert its investments in inventory and receivables into cash, which is particularly concerning given its negative net income and high leverage. This inefficiency may be a result of declining demand, as revenue has contracted for eight consecutive quarters, and could further pressure liquidity if not addressed.

The debt-to-equity ratio has increased sharply, not because of additional borrowing (total debt remained near $3.3B) but because equity has been eroded by massive losses and impairments. With EBITDA likely depressed, the D/EBITDA multiple of 22.91 in 2026Q2 is extremely high, suggesting that the company may face challenges in servicing its debt from operating cash flows. Interest coverage of 3.74 in 2026Q2, while positive, is thin and could deteriorate if earnings continue to decline, raising refinancing risk. Investors should monitor whether the company can generate sufficient EBITDA to bring D/EBITDA down to a more manageable level, as the current trajectory suggests increasing financial strain.

The current ratio of 2.32 appears healthy, but the quick ratio of 1.32 suggests that a significant portion of current assets is tied up in inventory, which may not be easily convertible to cash in a stress scenario. The decline in cash reserves, despite a stable current ratio, indicates that the company's liquidity position is weaker than it appears, especially given the high inventory levels and negative net income. Under severe stress, such as a further revenue decline or a tightening of credit markets, Perrigo may find it difficult to meet its short-term obligations without relying on additional debt or asset sales.